<DOC>
	<DOCNO>NCT00538915</DOCNO>
	<brief_summary>The purpose study determine NABI-IGIV ( 10 % ) [ Immune Globulin Intravenous ( Human ) , 10 % ] safe effective prevent serious bacterial infection ( SBIs ) treatment patient primary immune deficiency disorder ( PIDD ) compare historical control data .</brief_summary>
	<brief_title>Open Label , Phase III Study NABI-IGIV 10 % Immune Globulin Intravenous ( Human ) , 10 % In Subjects With Primary Immune Deficiency Disorders ( PIDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Male female , age ≥ 6 ≤ 75 , document confirmed preexist diagnosis chronic primary immune deficiency ( PIDD ) low total immunoglobulin G ( IgG ) level deficient antibody production chronic therapy ( i.e. , Xlinked agammaglobulinemia , common variable immunodeficiency ( CVID ) , Hyper IgM Syndrome immunoglobulin G ( IgG ) deficiency , etc ) . Currently immune globulin intravenous ( IGIV ) replacement therapy fix interval dosage total monthly dose immune globulin intravenous ( IGIV ) 300 800 mg/kg stable least 3 month prior screen . Documented ( within 3 month ) plasma immunoglobulin G ( IgG ) trough level &gt; 500 mg/dL current immunoglobulin G ( IgG ) therapy [ immunoglobulin G ( IgG ) level may obtain screen previous result available ] . Medical record document infection treatment within previous 2 year need available review . Subject legal guardian ( ) must give write informed consent/assent . If menstruating female , negative serum urine pregnancy test within 7 day prior first dose NabiIGIV [ immune globulin intravenous ( Human ) 10 % ] agree use acceptable method contraception least one year postmenopausal surgically sterile . Received blood product [ immune globulin intravenous ( IGIV ) ] within last 3 month prior screen receive investigational agent [ immune globulin intravenous ( IGIV ) ] within last four week prior receive NabiIGIV [ immune globulin intravenous ( Human ) 10 % ] . Known history medically significant adverse reaction immunoglobulin G ( IgG ) blood product . Known selective immunoglobulin A ( IgA ) deficiency , history allergic reaction product contain immunoglobulin A ( IgA ) history antibody immunoglobulin A ( IgA ) . Known significant proteinuria and/or history acute renal failure/or severe renal impairment [ blood urea nitrogen ( BUN ) creatinine 1.5 time upper limit normal ] . Known history current diagnosis deep venous thrombosis . Known medical condition know cause secondary immune deficiency , chronic lymphocytic leukemia , lymphoma , multiple myeloma , human immunodeficiency virus ( HIV ) infection , acquire immunodeficiency syndrome ( AIDS ) , chronic recurrent neutropenia ( absolute neutrophil count le 500 mm3 ) . Current daily use corticosteroid ( &gt; 10 mg prednisone equivalent /day &gt; 30 day ) , immunosuppressants immunomodulators . ( Intermittent corticosteroid use study allowable , medically necessary . ) Known noncontrollable arterial hypertension ( systolic blood pressure ( BP ) &gt; 160 mmHg /or diastolic BP &gt; 100 mmHg . ) Known anemia screening ( hemoglobin &lt; 10 g/dL ) . Subject pregnant lactating . Known history illicit drug use within 3 month prior administration investigational product study duration . Have condition judge study physician preclude participation study , include psychological disorder , might hinder compliance . Known active viral bacterial infection symptoms/signs consistent infection within two week prior initial dose investigational product infusion . Subjects may antibiotics long signs/symptoms infection absent two week prior initial infusion investigational product ( IP ) . Expectation noncompliance protocol procedure visit schedule .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>immunodeficiency</keyword>
	<keyword>humoral immunity</keyword>
	<keyword>antibody deficiency</keyword>
	<keyword>PID</keyword>
	<keyword>PIDD</keyword>
</DOC>